लोड हो रहा है...

Evaluating immune responses after sipuleucel-T therapy

Following FDA approval of sipuleucel-T in 2010 for metastatic castration resistant prostate cancer (mCRPC), several studies have described the effect of sipuleucel-T on peripheral immune responses. Retrospective associations have also been made with immune responses and survival. A recently publishe...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Cancer Biol Ther
मुख्य लेखकों: Strauss, Julius, Madan, Ravi A, Figg, William D
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Taylor & Francis 2015
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622939/
https://ncbi.nlm.nih.gov/pubmed/26054644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1056417
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!